Cidara Therapeutics Inc., A Subsidiary Of Merck & Co., Inc. (rahway, New Jersey Usa)
Clinical trials sponsored by Cidara Therapeutics Inc., A Subsidiary Of Merck & Co., Inc. (rahway, New Jersey Usa), explained in plain language.
A biotech developing antifungal therapies, subsidiary of Merck.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
One-Shot flu prevention? new drug aims to protect High-Risk groups all season
Prevention OngoingThis phase 3 trial is testing whether a single dose of CD388, a long-acting antiviral injection, can prevent the flu in 10,000 adults and teens at higher risk of complications. Participants receive either CD388 or a placebo and are monitored for flu-like illness over 24 weeks. Th…
Phase: PHASE3 • Sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
New antiviral shot could boost flu protection when given with vaccine
Prevention OngoingThis early-stage trial is testing whether a new long-acting antiviral medicine called CD388 can be safely given at the same time as the high-dose flu vaccine. About 100 healthy adults aged 18 to 49 will receive either the vaccine plus CD388 or the vaccine plus a placebo. Research…
Phase: PHASE1 • Sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC
-
Yearly flu shot alternative? new drug tested for Long-Term safety
Prevention OngoingThis study tests the safety of giving repeated annual doses of an experimental drug called CD388 to healthy adults. About 400 people who already tolerated one dose without serious side effects will receive two more doses over two years. Researchers will monitor for side effects a…
Phase: PHASE2 • Sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Prevention
Last updated Jun 27, 2026 08:07 UTC